#China #Xi'an #Tianlong #Blood Safety #HIV Testing

Enhancing Transfusion Safety with Innovative Solutions

On November 28, 2025, Tianlong Science and Technology reaffirmed its dedication to improving worldwide transfusion safety by unveiling an integrated blood screening solution on the occasion of World AIDS Day. This groundbreaking technology combines advanced automation with high-sensitivity nucleic acid testing (NAT) reagents, marking a significant step forward in detecting low viral load infections. This development is crucial for reducing the transmission of HIV through transfusions, thereby safeguarding patients who rely on safe blood supplies.

A Fully Automated Workflow for Blood Screening

At the core of Tianlong's initiative is the Aurora PANA X6, a fully automated nucleic acid extraction system designed for blood transfusion centers and large-scale screening programs. This solution, when coupled with the Gentier 96 real-time PCR system, creates a streamlined process for sampling and results reporting. It incorporates multiple features such as original tube loading, barcode identification, automated cap removal, direct sample pooling, nucleic acid extraction, and PCR preparation and amplification. By automating these processes, Tianlong significantly reduces manual steps, thereby lowering contamination risks and enhancing operational safety.

High Throughput for High Volume Blood Screening

The Aurora PANA X6 is capable of processing up to 576 samples per cycle, equating to a staggering 1,152 samples per day. This capacity is essential for high-volume screening demands. Its automated tube capping and decapping features ensure consistent operations with minimal contamination.

Flexible Pooling Modes for Efficiency

The system allows for direct pooling into deep well plates, eliminating the need for extra collection tubes. It supports both individual and 6-in-1 pooled testing, enabling laboratories to balance sensitivity and efficiency effectively. To ensure reliable performance, the platform features independent work areas, HEPA filtration, ultraviolet disinfection, controlled airflow, and a spill-resistant design, providing robust biosafety in demanding laboratory settings.

High-Sensitivity NAT Reagents for Detecting Low Viral Loads

Tianlong’s high-sensitivity NAT reagents complement its automated platform, utilizing qualitative real-time PCR in an all-in-one format that includes extraction and amplification. This reagent kit is specifically designed to detect HBV, HCV, HIV-1, and HIV-2, even at low viral loads, allowing laboratories to identify infections during latency. This is pivotal in minimizing the risks of transfusion-transmitted diseases and enhancing overall blood supply safety.

On this World AIDS Day, the ability to detect infections early underscores a collective commitment to protecting lives linked to blood donation and transfusion.

Committing to Safer Transfusions Daily

“As we observe World AIDS Day, we are reminded that each safe transfusion is a promise of protection for another human life,” stated Li Ming, CEO of Tianlong. “Our mission is to equip laboratories with solutions that enhance precision, bolster biosafety, and support the global effort to prevent HIV transmission.”

About Tianlong

Tianlong Science and Technology, established in 1997, is a pioneering company in genetic testing and molecular diagnostics. Alongside its group company, Shanghai Kehua Bio-engineering Co., Ltd. (KHB), Tianlong has developed five key technological platforms: immunodiagnostic, biochemistry, molecular diagnostics, point-of-care testing (POCT), and mass spectrometry. These platforms specialize in research, development, and manufacturing of in vitro diagnostic (IVD) instruments and reagents. Tianlong provides comprehensive solutions across a wide range of sectors, including clinical diagnostics, blood transfusion centers, disease control, veterinary outbreak prevention, and food safety.

For further information, please visit Tianlong's official website or check their LinkedIn, Facebook, or Twitter pages.